With a team of dedicated specialists, the New Mexico Cancer Center uses the latest technology, from blood tests and imaging ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

FDA approves Bayer's Nubeqa with ADT for metastatic hormone-sensitive prostate cancer, cutting death risk by 46%. Read more ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Dr. Angela Jia discussed How Better Treatments and Better Selection Can Improve Patient Outcomes in Localized Prostate Cancer. Dr. Jia discussed two important abstracts presented during the session: ...

Bayer said it received approval from the Food and Drug Administration for its drug Nubeqa, which treats patients with a certain type of prostate cancer.

The rollout marks a new chapter for men with prostate cancer, the most common cancer in Canadian men aside from skin cancer, ...

Eric Morrow told his doctor about his family history of prostate cancer and asked if he needed testing. His doctor said no.